Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fortress Biotech, Inc. (Nasdaq: FBIO) SEC filings page on Stock Titan provides access to the company’s regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8-K, registration statements such as Form S-1, and other periodic disclosures that describe material events, financing arrangements and portfolio developments across Fortress and its subsidiaries.
Recent Form 8-K filings detail items such as amendments to the company’s credit agreement with Oaktree Fund Administration, LLC, including an extension of the loan maturity date and revised financial covenants tied to product net sales at Journey Medical Corporation. They also describe the issuance of warrants to purchase shares of Fortress common stock, with terms such as exercise price, anti-dilution adjustments and expiration date. Other 8-Ks report FDA-related milestones, including the issuance of a Complete Response Letter for CUTX-101, subsequent resubmission of the New Drug Application by Sentynl Therapeutics, and Fortress’ press releases on quarterly financial results.
The Form S-1 registration statement reproduced in part here explains Fortress Biotech’s business model, outlines its network of subsidiaries and partner companies, and registers the resale of shares issuable upon exercise of warrants granted in connection with its credit facility. It also describes risk factors, forward-looking statements and other information relevant to investors evaluating FBIO securities.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight key terms, financial obligations and corporate actions, helping readers quickly understand the implications of documents that can span many pages. Users can review filings related to common stock and preferred stock listed on the Nasdaq Capital Market, as well as disclosures about royalty arrangements, subsidiary transactions and regulatory events that may affect Fortress Biotech’s capital structure and operations.
Fortress Biotech, Inc. Chief Financial Officer David Jin acquired 2,967 shares of common stock at $2.176 per share through the company’s Employee Stock Purchase Plan. This grant was reported as exempt under Rule 16b-3(d) and Rule 16b-3(c). After the transaction, he holds 1,251,571 shares in total, including 1,230,000 shares underlying deferred restricted stock units, so the new purchase represents a small portion of his overall position.
Fortress Biotech, Inc. is a biopharmaceutical holding and operating company that acquires, develops and monetizes drug assets through a network of subsidiaries and partner companies. It focuses on product revenue, equity stakes, dividends and royalties across dermatology, oncology, rare disease and gene therapy.
As of March 25, 2026, Fortress had 32,202,564 common shares and 3,427,138 shares of 9.375% Series A preferred stock outstanding, with non‑affiliate common equity valued at $43,741,728 as of its most recent second fiscal quarter. The company reports 78 full‑time employees across Fortress and its controlled entities.
Recent transactions reshaped the portfolio. Sun Pharma acquired former subsidiary Checkpoint, giving Fortress $28.0 million in cash plus potential royalties and up to $4.8 million tied to EU approval of UNLOXCYT. Cyprium’s Menkes disease therapy ZYCUBO won FDA approval, with up to $128 million in potential sales milestones and tiered royalties, and Cyprium sold its priority review voucher for $205 million. Additional upside comes from Journey’s launch of EMROSI for rosacea, an exclusive license for Avenue’s ATX‑04 in lysosomal storage diseases, Urica’s equity and royalty position in Crystalys’ Phase 3 gout program, and multiple late‑stage and mid‑stage programs in CMV vaccines, GBM CAR‑T, and other rare and neurological diseases.
Fortress Biotech reported 2025 results showing a sharp improvement in profitability driven by asset monetizations and partner activity. Net revenue was $63.3 million for the year ended December 31, 2025, up from $57.7 million in 2024, mainly from product and other revenue.
Net income attributable to Fortress was $6.8 million, compared with a loss of $46.0 million in 2024, helped by a $27.1 million gain from deconsolidation of a subsidiary and $17.6 million of other income. Net loss attributable to common stockholders narrowed to $1.9 million, or $(0.07) per share.
Operationally, the FDA approved ZYCUBO for Menkes disease, and subsidiary Cyprium sold a Rare Pediatric Disease Priority Review Voucher for $205 million, with potential tiered royalties and up to approximately $128 million in sales milestones. The Checkpoint Therapeutics acquisition by Sun Pharma created eligibility for up to an additional $4.8 million under a contingent value right plus a 2.5% royalty on UNLOXCYT sales. Fortress also holds a 3% royalty on dotinurad sales through Crystalys Therapeutics.
Fortress Biotech reported that its majority-owned subsidiary Cyprium Therapeutics has closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds under a previously disclosed asset purchase agreement. In connection with the transaction, Cyprium redeemed all outstanding shares of its 9.375% Perpetual Preferred Stock.
Fortress, which owns 80.4% of Cyprium’s outstanding common stock on an as-converted basis, expects to receive at least $100.0 million from Cyprium through potential future dividends and intercompany agreements, including intercompany debt, interest and accrued expenses. Cyprium must pay 20% of the PRV sale proceeds to an institute of the National Institutes of Health and also remains eligible to receive tiered royalties on net sales of ZYCUBO and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics.
Fortress Biotech’s chairman, president and CEO Lindsay A. Rosenwald filed Amendment No. 5 to his Schedule 13D, reporting beneficial ownership of 6,917,715 shares of common stock, or 20.7% of the company, based on 31,037,937 shares outstanding as reported in a December 2025 prospectus supplement.
The position includes 4,050,765 issued shares held directly, 475,424 unvested restricted shares subject to repurchase, 2,330,874 shares underlying currently exercisable warrants, and smaller holdings through Paramount Biosciences, LLC and Capretti Grandi LLC over which he has voting and dispositive control. It excludes 96,919 shares held by family trusts where he lacks such control.
The amendment reflects equity grants of 454,153 shares on January 1, 2025 and 475,424 shares on March 18, 2026 under Fortress Biotech’s Long Term Incentive Plan, awarded after he achieved 100% of goals set by the compensation committee. Rosenwald states he has no present plans for major corporate actions or additional acquisitions or dispositions beyond this compensation-related ownership.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. reported that President, CEO & Chairman Lindsay A. Rosenwald received a grant of 475,424 shares of common stock on March 18, 2026. These are restricted shares awarded under the company’s Long-Term Incentive Plan, rather than an open-market purchase.
Following this equity award, Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. The transaction reflects stock-based compensation that further ties the executive’s interests to the company’s long-term performance.
WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.
Fortress Biotech’s majority-owned subsidiary Cyprium Therapeutics agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $205 million in cash, payable at closing. The voucher was granted after ZYCUBO was approved to treat Menkes disease in pediatric patients.
Fortress owns 80.4% of Cyprium’s common stock and expects to receive at least $100 million over time from Cyprium through dividends and intercompany arrangements, subject to closing, taxes, required payments to a National Institutes of Health institute, Cyprium’s preferred stock redemption and other obligations. Fortress also amended its Oaktree credit agreement to ease several financial covenants after the PRV sale and to apply $10 million of proceeds, plus interest and a yield protection premium, to mandatory loan prepayment.
Fortress Biotech, Inc. reported that the U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for the treatment of Menkes disease in pediatric patients. This represents regulatory clearance for a therapy aimed at a rare pediatric condition.
In connection with this FDA approval, a Rare Pediatric Disease Priority Review Voucher was issued and will be transferred to Cyprium Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech. The company furnished a press release with further details as an exhibit.
Fortress Biotech, Inc. filed Amendment No. 8 to its Schedule 13D for Avenue Therapeutics, Inc., reporting beneficial ownership of 439,955 shares of Avenue common stock, equal to 13.4% of the outstanding common shares. This total includes 250,000 shares of Class A preferred stock, which are convertible into 222 shares of common stock and are structured so that the Class A preferred will at all times constitute a voting majority. Fortress owns all outstanding Class A preferred shares, giving it majority voting control despite a minority economic stake.
Fortress’s ownership also reflects an Annual Equity Grant under a Founders Agreement, through which Avenue issues to Fortress each year shares equal to 2.5% of Avenue’s fully diluted outstanding equity. In addition, as holder of the Class A preferred, Fortress is entitled each January 1 to stock dividends in Avenue common equal to 2.5% of Avenue’s fully diluted outstanding capitalization. The filing notes 296 Avenue common shares underlying outstanding warrants granted by Fortress to two of its executives, with Fortress retaining sole voting power but shared dispositive power over those warrant shares.